CNBS Rallied Triple Digits On One Regulatory Bet, Not Dividends

The Amplify Seymour Cannabis ETF (NYSEARCA:CNBS) has rallied sharply in 2026, with shares up 105% over the past year and 9% in just the last week.

24/7 Wall Street • Jun 9, 2026

US Reclassifies Weed: Can Cannabis ETFs Give Your Portfolio a New High?

Medical marijuana's US reclassification revives cannabis ETFs like WEED, with tax relief and reform hopes fueling sharp gains across the sector.

Zacks Investment Research • May 14, 2026

Cannabis Rescheduling Could Unlock the Biggest MSO Rally Since 2021

Federal cannabis policy moved from theory to action this spring, and three ETFs sit closest to the trade.

24/7 Wall Street • May 6, 2026

Cannabis ETFs: Regulatory Momentum Returns Focus

Cannabis stocks have seen renewed investor interest as federal policy momentum improves. The most important recent development was the placement of FDA-approved marijuana products and state-regulated medical marijuana products from Schedule I to Schedule III under the Controlled Substances Act.

ETF Trends • Apr 30, 2026

The Last Cannabis ETFs Worth Your Money: Why Most Failed and 3 Are Still Trading

Cannabis ETFs entered 2026 after multiple fund closures, stalled federal reform, and a prolonged multi‑year drawdown in underlying equities.

24/7 Wall Street • Apr 23, 2026

After A Surprise Win In 2025, What Will 2026 Bring For The Amplify Cannabis ETF? | CNBS

Amplify Seymour Cannabis ETF (NYSEARCA:CNBS) posted a 17% gain in 2025, but that masks the real story.

24/7 Wall Street • Jan 2, 2026

CNBS: New Buy Rating On Cannabis ETF, Stoked By Positive Regulatory Trend

Amplify Seymour Cannabis ETF (CNBS) is positioned for upside as U.S. cannabis reclassification to Schedule III appears likely, marking a key industry milestone. CNBS exhibits extreme volatility, warranting only a small (1-3%) portfolio allocation; call options are not attractive due to high premiums. Current CNBS valuations—12x trailing earnings and 3x sales—are reasonable for a growth sector anticipating regulatory tailwinds.

Seeking Alpha • Dec 18, 2025

Cannabis ETF (CNBS) Hits New 52-Week High

CNBS Cannabis ETF climbs to a 52-week high, fueled by rescheduling optimism and potential further gains.

Zacks Investment Research • Dec 18, 2025

Cannabis ETFs: This Imminent Trigger Could Lead To A Definitive Repricing Of Assets

I recommend buying cannabis sector ETFs. Recent news suggests imminent U.S. regulatory easing, potentially reclassifying marijuana and unlocking significant sector value. Current MJ ETF price/sales is 1.5x; I conservatively project a move to 2.5x, implying 66% upside. Key risks include regulatory uncertainty, sector profitability challenges, and historical underperformance post-IPOs.

Seeking Alpha • Dec 17, 2025

6 Top-Performing ETF Areas of Last Week

Cannabis, metals, space and health care led ETF gains last week. WEED, CNBS, SIL, UFO, GDXJ, PLTM and OZEM outperformed despite tech weakness.

Zacks Investment Research • Dec 17, 2025